NextGen and Oxon Life Science Explore Opportunity for Scientific Collaboration
April 17 2008 - 6:30AM
Marketwired
LONDON, UNITED KINGDOM (PINK SHEETS: NXGB), a biotechnology
company that develops novel therapeutic proteins that disrupt the
advance of life-threatening cancers, today announced it has entered
into discussion about collaboration with Oxon Life Science
("Oxon"), from whom it has recently acquired use, commercialisation
and ownership rights of a patent application for the treatment of
cancer, regarding the development of the latest stem cell
technology that NXGB has acquired from Oxon in that
transaction.
NextGen CEO, Konstantinos Kardiasmenos, stated, "NextGen is
excited about the possibility of close collaboration with Oxon.
NextGen's proprietary technology, which we have acquired from Oxon,
has the potential to treat breast cancer by more precisely
targeting the cancer cells."
About NextGen Bioscience Inc.
NextGen is positioning itself as the world's leading bioscience
company in the development and commercial licensure of novel
therapeutic proteins that disrupt the advance of life-threatening
cancers. The company leverages cutting-edge research collaborations
to achieve breakthroughs in anti-cancer treatments, and then
licenses these patented drug product candidates to Big
Pharmaceutical and Biotechnology companies.
Statements about NextGen's future expectations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as the term is defined in the Private Litigation
Reform Act of 1995. NextGen's actual results could differ
materially from expected results. NextGen undertakes no obligation
to update forward-looking statements to reflect subsequently
occurring events or circumstances.
For more information about NextGen Bioscience Inc., or to
schedule an interview with Mr. Kardiasmenos, please contact
Investor Relations at +44 20 7247 8186 or
investorrelations@nextgenbioscience.com.
Contacts: NextGen Bioscience, Inc. Konstantinos Kardiasmenos +44
(0) 20 7247 8186 +44 (0) 20 7377 9454 (FAX) Email:
investorrelations@nextgenbioscience.com Website:
www.nextgenbioscience.com
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From Apr 2024 to May 2024
NxGen Brands (PK) (USOTC:NXGB)
Historical Stock Chart
From May 2023 to May 2024